Fresenius' Share Price Hits New Low Despite Solid Q1 and €591M Dividend Payout

Fresenius paid €591M dividend (€1.05/share) despite stock at 52-week low. Q1 revenue grew 5%, operating cash flow surged, but FME stake remains a concern.

Fresenius shareholders collected roughly €591 million this week, as the company paid out €1.05 per share for each of the more than 563 million eligible shares. The payout, approved by the annual general meeting with 99.99% support and representing nearly 77% of the capital, marks a 5% increase from last year's dividend. But the timing could hardly be more challenging: the stock closed Thursday at €36.45 — precisely a 52-week low. Since the start of 2026 the shares have shed about 24%, while the decline from the February peak of €52.10 amounts to 30%.

Behind the headline figure lies a deliberate financial strategy. The payout ratio of 37% sits in the upper half of Fresenius' self-imposed corridor of 30% to 40% of core net income. By staying within that band, management signals it is preserving investment capacity while still rewarding shareholders. The dividend is not consuming the cash needed for operational or strategic moves.

That cash position is underpinned by the recent first-quarter results. Fresenius reported organic revenue growth of 5% to €5.744 billion, driven by Fresenius Kabi with €2.150 billion and Helios with €3.501 billion. Adjusted EBIT rose from €654 million to €678 million, with the margin at 11.8%. Core earnings per share — calculated excluding FME and Vitrea — climbed 13% to €0.82. More striking was the leap in operating cash flow: €389 million versus just €95 million in the year-earlier quarter, a swing Fresenius attributes to timing effects at Helios and net working capital improvements at Kabi.

While the operating core holds steady, the company faces a persistent overhang from its stake in Fresenius Medical Care. FME has just launched a new share buyback programme totalling around €1 billion, with an initial tranche of up to €600 million. Fresenius holds roughly 29% of FME. During FME's previous buyback in August 2025, Fresenius sold its own shares at the same pace to keep the ownership level unchanged — avoiding an automatic increase from the cancellation of repurchased stock. Whether it will follow the same approach this time remains unconfirmed, but the pattern is well established.

Fresenius has already raised substantial sums from FME-related transactions. In March 2025 it placed 10.6 million FME shares at €44.50, and issued €600 million in convertible bonds tied to FME equity, bringing in gross proceeds of around €1.1 billion. Additionally, it collected €121 million in dividends from the subsidiary in fiscal 2025. These figures underscore why every capital action at FME is closely monitored by the parent.

Looking ahead, management has maintained its guidance for the full year 2026: organic revenue growth of 4% to 7%, and a currency-adjusted core earnings per share gain of 5% to 10%. The next scheduled update comes on 5 August 2026 with the half-year results. Until then, the question is whether the underlying operational strength — revenue momentum, margin discipline, and cash generation — can outweigh the negative sentiment that has dragged the stock to its lowest point in a year.